{"entity":{"type":"insider","cik":"0001762202","url":"/insider/0001762202","json_url":"/insider/0001762202.json","name":"Blackstone Clarus III L.L.C.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":10,"n_filings":4,"first":"2020-07-30","last":"2021-07-20","span_basis":"filed_date"},"name_variants":[{"name":"Blackstone Clarus III L.L.C.","source":"filing","n_filings":4,"first_seen":"2020-07-30","last_seen":"2021-07-20"}],"transactions":[{"id":4276845,"accession":"0001567619-21-013733","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-21-013733","line_url":"/filing/0001567619-21-013733#line-4","is_derivative":false,"issuer_cik":"0001070844","issuer_name":"Imago BioSciences, Inc.","issuer_ticker":"IMGO","issuer_name_source":null,"issuer_url":"/issuer/0001070844","owner_cik":null,"owner_name":"Blackstone Holdings I/II GP L.L.C.; Blackstone Clarus III L.L.C.; Clarus Ventures III GP, L.P.; SCHWARZMAN STEPHEN A; Clarus Lifesciences III, L.P.; Blackstone Group Management L.L.C.; Blackstone Holdings II L.P.; Blackstone Group Inc","owner_display_name":"Blackstone Holdings I/II GP L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2400000.0,"total_display":"2,400,000.00","total_whole":"2,400,000","shares_owned_after":3375037.0,"shares_owned_after_display":"3,375,037","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-20","filed_date":"2021-07-20","scope":"insider"},{"id":4351545,"accession":"0000899243-21-019456","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0000899243-21-019456","line_url":"/filing/0000899243-21-019456","is_derivative":false,"issuer_cik":"0001070844","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001070844","owner_cik":null,"owner_name":"Blackstone Clarus III L.L.C.; SCHWARZMAN STEPHEN A; Blackstone Holdings I L.P.; Blackstone Group Inc; Blackstone Holdings I/II GP L.L.C.; Clarus Lifesciences III, L.P.; Blackstone Holdings II L.P.; Blackstone Clarus GP L.P.; Clarus Ventures III GP, L.P.; Blackstone Group Management L.L.C.","owner_display_name":"Blackstone Clarus III L.L.C.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":510000.0,"total_display":"510,000.00","total_whole":"510,000","shares_owned_after":4875730.0,"shares_owned_after_display":"4,875,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-14","scope":"insider","n_lines":7},{"id":3280126,"accession":"0000899243-20-026702","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-026702","line_url":"/filing/0000899243-20-026702#line-3","is_derivative":false,"issuer_cik":"0001070844","issuer_name":"GRAYBUG VISION, INC.","issuer_ticker":"GRAY","issuer_name_source":null,"issuer_url":"/issuer/0001070844","owner_cik":null,"owner_name":"Clarus Ventures III GP, L.P.; SCHWARZMAN STEPHEN A; Blackstone Clarus III L.L.C.; Blackstone Group Inc; Blackstone Holdings II L.P.; Clarus Lifesciences III, L.P.; Blackstone Holdings I/II GP L.L.C.; Blackstone Group Management L.L.C.","owner_display_name":"Clarus Ventures III GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","total_whole":"4,000,000","shares_owned_after":1930395.0,"shares_owned_after_display":"1,930,395","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-29","filed_date":"2020-10-01","scope":"insider"},{"id":3195407,"accession":"0000899243-20-020805","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-20-020805","line_url":"/filing/0000899243-20-020805#line-5","is_derivative":false,"issuer_cik":"0001070844","issuer_name":"Annexon, Inc.","issuer_ticker":"ANNX","issuer_name_source":null,"issuer_url":"/issuer/0001070844","owner_cik":null,"owner_name":"SCHWARZMAN STEPHEN A; Blackstone Holdings I/II GP L.L.C.; Blackstone Holdings II L.P.; Clarus Ventures III GP, L.P.; Blackstone Group Inc; Blackstone Group Management L.L.C.; Clarus Lifesciences III, L.P.; Blackstone Clarus III L.L.C.","owner_display_name":"SCHWARZMAN STEPHEN A","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":3400000.0,"total_display":"3,400,000.00","total_whole":"3,400,000","shares_owned_after":2730635.0,"shares_owned_after_display":"2,730,635","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-28","filed_date":"2020-07-30","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001623715","name":"Imago BioSciences, Inc.","url":"/issuer/0001623715","role":"Ten percent owner","n_filings":1,"first_seen":"2021-07-20","last_seen":"2021-07-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001827506","name":"Talaris Therapeutics, Inc.","url":"/issuer/0001827506","role":"Ten percent owner","n_filings":1,"first_seen":"2021-05-14","last_seen":"2021-05-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001534133","name":"GRAYBUG VISION, INC.","url":"/issuer/0001534133","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-01","last_seen":"2020-10-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001528115","name":"Annexon, Inc.","url":"/issuer/0001528115","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-30","last_seen":"2020-07-30"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001762202","retrieved_at":"2026-08-23T22:13:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}